Transgene SA is a clinical-stage biotechnology company headquartered in Illkirch-Graffenstaden, France, that specializes in the design and development of virus-based immunotherapies for cancer treatment. Leveraging proprietary vectorization technology, the company engineers oncolytic viruses and therapeutic vaccines to stimulate the body’s immune response against solid tumors. Transgene’s research platform integrates genetic payloads encoding immunomodulatory molecules, aiming to enhance both innate and adaptive anti-tumor activity.
The company’s pipeline includes several lead candidates at various stages of clinical development. TG4001 is an HPV-targeted therapeutic vaccine intended for HPV-associated lesions and cancers, while TG4050 is a personalized neoantigen vaccine program designed to generate patient-specific immune responses. Transgene is also advancing oncolytic virus candidates such as TG6002, which combines oncolytic activity with intratumoral expression of cytosine deaminase to convert a prodrug into an active anticancer agent within the tumor microenvironment.
Transgene maintains a global footprint through strategic collaborations and partnerships with pharmaceutical and academic institutions. These alliances support clinical trials, manufacturing scale-up, and regulatory activities across Europe and North America. The company has established collaborations with leading oncology research centers, enabling access to specialized patient populations and cutting-edge translational science.
Founded in 1979, Transgene has grown into one of Europe’s pioneering biotech enterprises in the immuno-oncology sector. Under the guidance of an experienced management team, the company continues to expand its R&D capabilities and strengthen its intellectual property portfolio. Transgene remains focused on advancing its pipeline, forging new partnerships, and ultimately delivering innovative immunotherapies to patients in need.
AI Generated. May Contain Errors.
MarketBeat All Access